Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following virtual investor conferences in September:

To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery ? all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune's 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.

These press releases may also interest you

23 oct 2021
NOVA OCULUS PARTNERS, LLC has reached a settlement with the Securities and Exchange Commission (SEC) that ends the SEC's enforcement action against the company. The settlement (Case # 5:18-cv-00701-FLA-SP; U.S. District Court for the Central District...

23 oct 2021
What is PICC Guard? PICC Guard is a United States founded medical start-up that believes in transforming lives through medical innovation. The co-founders are seasoned medical professionals who emphasize accountability, quality and improving our...

23 oct 2021
The Thermometer market will register an incremental spend of about USD 0.61 Billion, growing at a CAGR of 8.63% during the five-year forecast period. A targeted strategic approach to Thermometer sourcing can unlock several opportunities for buyers....

23 oct 2021
Columbia China, a joint venture between Seattle's Columbia Pacific Management, Sheares Healthcare Group, a 100% owned subsidiary of Singapore investment company Temasek, and Hong Kong-based conglomerate Swire Pacific Limited, opens its third &...

23 oct 2021
Polaris Biology, a leading innovator in single-cell technologies, announced today the largest product launch in company history with the introduction of the Stariontm Mass Cytometry System. The next-generation mass cytometer has brought in a...

23 oct 2021
Charcuterie L. Fortin Ltée. is recalling Charcuterie Fortin brand Salami from the marketplace because it may contain wheat which is not declared on the label. People who have an allergy to wheat or have celiac disease or other gluten-related...

News published on 1 september 2021 at 16:10 and distributed by: